Istradefylline Patent Expiration
Istradefylline is Used for managing off time in patients with Parkinson's disease undergoing L-DOPA therapy. It was first introduced by Kyowa Kirin Inc
Istradefylline Patents
Given below is the list of patents protecting Istradefylline, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Nourianz | US7727993 | Administering adenosine A2A receptor antagonist to reduce or suppress side effects of parkinson's disease therapy | Jan 28, 2028 | Kyowa Kirin |
| Nourianz | US8318201 | Method of stabilizing diarylvinylene compound | Sep 05, 2027 | Kyowa Kirin |
| Nourianz | US7541363 | Microcrystal |
Nov 13, 2024
(Expired) | Kyowa Kirin |
| Nourianz | US7727994 | Methods of treating patients suffering from movement disorders |
Jan 18, 2023
(Expired) | Kyowa Kirin |
Istradefylline's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List